DB05383InvestigationalSmall molecule
Pimagedine has been developed by Synvista Therapeutics, Inc for the treatment of diabetic kidney disease. It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or... It is beneficial in treating patients with diabetic nephropathy.
- Mechanism
- Curator reviewed
Pimagedine reportedly inhibits the formation of glycosylated proteins (advanced glycosylation end-products) and has other actions including inhibition of aldose reductase.
- Primary indication
- Investigated for use/treatment in diabetic kidney disease.Curator reviewed
- Formula / weight
- CH6N4 · 74.0851 g/mol (avg)
- Also known as
- Aminate base · Aminoguanidine · Guanyl hydrazine · Hydrazinecarboximidamide · Monoaminoguanidine
Resolves to
Clinical / RWD
Structure
InChIKey
HAMNKKUPIHEESI-UHFFFAOYSA-NSMILESNNC(N)=NTransporters
What you can answer from here — as of September 13, 2026
5Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Pimagedine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account